Search Results for “cancer” – Page 152

Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that a development milestone for cabiralizumab has been achieved, triggering a $25 million payment from Bristol-Myers Squibb Company (BMS) (BMY) under the license and collaboration agreement between the companies established in 2015. The milestone was triggered by initiation of a multi-arm Phase 2 clinical trial (NCT03336216), sponsored by Bristol-Myers Squibb Company, evaluating cabiralizumab and Opdivo® (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. “Effective treatment for patients with pancreatic cancer remains a significant unmet need and is a cancer for which existing immunotherapies have not been successful to date,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “We are encouraged by the preliminary data presented at SITC 2017 and are pleased to see this trial underway.” The Phase 2 trial is expected to enroll approximately 160 ...

Source: finance.yahoo
540
January 31, 2018

Sanofi snaps up Ablynx for 3.9bn euros

Sanofi will launch public offers to acquire all shares, including ADSs, warrants and convertible bonds of Ablynx. News of the deal will no doubt come as a great disappointment to Novo Nordisk, which recently stepped up its efforts to buy Ablynx with a second offer valued at around 2.6 billion euros.

Source: Currenthollywood
637
January 30, 2018

Market Views Sanofi Ablynx

Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Novartis AG (NYSE: NVS) today announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.

Source: Novartis
485
January 29, 2018

FDA GEP-NETs Lutathera® New Approvals

Tiny implant opens way to deliver drugs deep into the brain

Scientists have created a hair-thin implant that can drip medications deep into the brain by remote control and with pinpoint precision.

Source: CT Post
547
January 29, 2018

cancer medical device Parkinson’s disease Researches

AstraZeneca’s PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy.

Source: finance.yahoo
671
January 26, 2018

cancer inhibitor New Approvals ovarian

Tmunity nabs $100M for next-gen T-cell immunotherapies

Tmunity Therapeutics is looking to bring better and safer T-cell therapies for both solid tumors and blood cancers and has scored a $100 million series A to propel it on its journey

Source: fiercebiotech
495
January 26, 2018

blood cancer Series solid tumor T-cell therapies

Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.

Source: Cnbc
976
January 24, 2018

cancer CAR–T Market Views

The Effects Of Air Pollution On Human Health

Although it isn’t talked about often, older adults in the United States are turning to drugs and alcohol at an alarming rate. Studies have found that a large population of older Americans are suffering from substance use disorders, and the number is only expected to rise. According to research, the number of Americans aged 50 and older struggling with addiction is expected to nearly double in the coming years, going from 2.8 million to 5.7 million by 2020.

Source: msn
1,025
January 24, 2018

air pollution asthma cardiovascular pneumonia

Biosimilar Avastin wins EU approval

European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. The drug has been cleared to treat a range of indications spanning carcinoma of the colon or rectum, breast cancer; nonsquamous non-small cell lung cancer, renal cell cancer; platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer. The companies noted that the approval came after trial data showed a high degree of similarity between Mvasi (biosimilar bevacizumab) and its reference drug, “with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products”. Mvasi is the first product borne out of an alliance between Amgen and Allergan to bag marketing authorisation from the European Commission, “highlighting the success of our joint commitment to developing cancer biosimilars,” noted David Nicholson, chief research and development officer at ...

Source: Pharmatimes
560
January 23, 2018

Avastin Mvasi New Approvals Roche

Diagnostic Products of the Future

Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.

Source: MDDI Online
769
January 23, 2018

diagnostics healthcare technologies and innovations medical device Researches

Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

Sanofi snaps up Ablynx for 3.9bn euros

Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Tiny implant opens way to deliver drugs deep into the brain

AstraZeneca’s PARP Inhibitor Lynparza Gets Approval in Japan

Tmunity nabs $100M for next-gen T-cell immunotherapies

Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

The Effects Of Air Pollution On Human Health

Biosimilar Avastin wins EU approval

Diagnostic Products of the Future

Trending Topics

Hot Tags

Subscribe

more

more

Customer Services

About Us

Buy on Drugdu.com

Sell on Drugdu.com

Blogroll

Free APP

Follow Us